: OncoGenex initiated with an Outperform at William BlairTarget $21. :theflyonthewall.com
http://www.williamblair.com/Pages/news_story_dept.asp?uid=1896&depID=4"OncoGenex's lead candidate custirsen (partnered with Teva) is in two Phase III studies, and both are expected to release top-line data during fourth quarter 2012." People pay money to hear from analysts who cant even get simple information right, such as when the trials will end. I refuse to discuss/assign merit to his price target.